stoxline Quote Chart Rank Option Currency Glossary
  
Novo Nordisk A/S (NVO)
77.87  -0.96 (-1.22%)    02-14 16:00
Open: 78.58
High: 79.0663
Volume: 9,860,416
  
Pre. Close: 78.83
Low: 77.82
Market Cap: 346,815(M)
Technical analysis
2025-02-14 4:50:14 PM
Short term     
Mid term     
Targets 6-month :  99.66 1-year :  105.08
Resists First :  85.33 Second :  89.97
Pivot price 83.81
Supports First :  77.82 Second :  64.75
MAs MA(5) :  81.22 MA(20) :  83.33
MA(100) :  101.74 MA(250) :  120.1
MACD MACD :  -2.3 Signal :  -2.2
%K %D K(14,3) :  5.5 D(3) :  17.9
RSI RSI(14): 34.1
52-week High :  148.14 Low :  77.82
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NVO ] has closed below the lower bollinger band by 5.6%. Bollinger Bands are 29.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 79.58 - 80.35 80.35 - 80.81
Low: 76.18 - 77.19 77.19 - 77.8
Close: 76.72 - 78.35 78.35 - 79.34
Company Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headline News

Mon, 17 Feb 2025
Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.1% - What's Next? - MarketBeat

Mon, 17 Feb 2025
Novo Nordisk A/S (NYSE:NVO) Shares Bought by Wealth Quarterback LLC - MarketBeat

Mon, 17 Feb 2025
Novo Nordisk A/S (NVO): Among the Best Drug Stocks to Buy Now - Yahoo Finance

Sun, 16 Feb 2025
2 Important Insights From Novo Nordisk's Earnings Call - The Motley Fool

Sat, 15 Feb 2025
Eli Lilly, Novo stocks in focus as RFK Jr. leads HHS (NVO:NYSE) - Seeking Alpha

Fri, 14 Feb 2025
NVO STOCK NEWS: NVO Shareholders with Large Losses Should - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 3,360 (M)
Shares Float 3,190 (M)
Held by Insiders 0 (%)
Held by Institutions 10.1 (%)
Shares Short 8,270 (K)
Shares Short P.Month 4,700 (K)
Stock Financials
EPS 2.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 27.06
Profit Margin 35 %
Operating Margin 47.4 %
Return on Assets (ttm) 21.4 %
Return on Equity (ttm) 88.7 %
Qtrly Rev. Growth 21.3 %
Gross Profit (p.s.) 68.17
Sales Per Share 80.52
EBITDA (p.s.) 37.91
Qtrly Earnings Growth 22.3 %
Operating Cash Flow 118,220 (M)
Levered Free Cash Flow 46,040 (M)
Stock Valuations
PE Ratio 26.3
PEG Ratio 0
Price to Book value 2.87
Price to Sales 0.96
Price to Cash Flow 2.21
Stock Dividends
Dividend 0.5
Forward Dividend 0
Dividend Yield 0.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android